Conclusions
DDIs
Adavosertib, when administered at a dose of 225 mg bid, is a weak inhibitor of CYP1A2, CYP2C19, and CYP3A and therefore has a low risk of causing clinically significant DDIs with drugs metabolized by these enzymes.